Validation of a German version of the International Hip Outcome Tool 12 (iHOT12) according to the COSMIN checklist

Baumann, Florian; Popp, Daniel; Müller, Karolina; Müller, Michael; Schmitz, Paul; Nerlich, Michael; Fickert, Stefan

doi:10.1186/s12955-016-0407-9

Cited by 31 publications

(40 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The iHOT-12 uses 12 questions from the original 33 and accounts for 96-99% of the total variation of the full score, based on regression analysis, and covers all four domains of the iHOT-33 [4]. It is now included as part of the minimal dataset in both the British and Swedish non-arthroplasty hip registries [12,13] and has been validated in many languages [14][15][16]. Despite this, there are still uncertainties as to what particular postoperative scores actually mean to the patient.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the patient acceptable symptom state following hip arthroscopy using the 12 item international hip outcome tool

Robinson

Maempel

Rankin

et al. 2020

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background: The International Hip Outcome Tool 12 (iHOT-12) is a shorter version of the iHOT-33 which measures health related quality of life following treatment of hip disorders in young, active patients. The purpose of this study was identify a PASS threshold for a UK population undergoing hip arthroscopy for intra-articular hip pathology. Methods: Data was identified retrospectively from a prospective database of patients undergoing hip arthroscopy under the care of a single surgeon within the date range January 2013 to March 2017. All patients with a diagnosis of femoroacetabular impingment (FAI) undergoing arthroscopic treatment were included. iHOT-12, EuroQol 5D-5 L (EQ-5D-5 L) and a satisfaction questionnaire were available pre and post-operatively. PASS was calculated using an anchor-based approach and receiver operator characteristic (ROC) analysis.Results: 171 patients underwent hip arthroscopy in the study period. Linked longitudinal follow-up data was available for 122 patients (71.3%) at a median of 24.3 months (740 days, interquartile range 576-1047). The PASS threshold for the iHOT-12 was 59.5 (sensitivity 81.1%, specificity 83.9%; area under the curve (AUC) 0.92, 95% CI 0.87-0.97). 64% of patients achieved this score. The median postoperative iHOT-12 score was 72.5 (IQR 44) and the mean change in score was 35 (SD 25, p < 0.001). The EQ-5D Index improved by 0.18 (SD 0.25, p < 0.001) and there was a mean change of 7.67 (SD 24.82) on the EQ-5D VAS (p = 0.001). Conclusions:We report a PASS threshold of the iHOT-12 following hip arthroscopy for FAI as a measurable benchmark for clinicians using this outcome measure.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of the patient acceptable symptom state following hip arthroscopy using the 12 item international hip outcome tool

Robinson

Maempel

Rankin

et al. 2020

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…Out of 803 articles found, 20 full texts were assessed for eligibility27–46 and 10 studies were included in the qualitative synthesis 27 28 32 36 37 39–41 45 46. The flow chart of the literature search for the updated SR is presented in figure 2.…”

Section: Methodsmentioning

confidence: 99%

Patient-reported outcome measures for hip-related pain: a review of the available evidence and a consensus statement from the International Hip-related Pain Research Network, Zurich 2018

et al. 2020

View full text Add to dashboard Cite

Hip-related pain is a well-recognised complaint among active young and middle-aged active adults. People experiencing hip-related disorders commonly report pain and reduced functional capacity, including difficulties in executing activities of daily living. Patient-reported outcome measures (PROMs) are essential to accurately examine and compare the effects of different treatments on disability in those with hip pain. In November 2018, 38 researchers and clinicians working in the field of hip-related pain met in Zurich, Switzerland for the first International Hip-related Pain Research Network meeting. Prior to the meeting, evidence summaries were developed relating to four prioritised themes. This paper discusses the available evidence and consensus process from which recommendations were made regarding the appropriate use of PROMs to assess disability in young and middle-aged active adults with hip-related pain. Our process to gain consensus had five steps: (1) systematic review of systematic reviews; (2) preliminary discussion within the working group; (3) update of the more recent high-quality systematic review and examination of the psychometric properties of PROMs according to established guidelines; (4) formulation of the recommendations considering the limitations of the PROMs derived from the examination of their quality; and (5) voting and consensus. Out of 102 articles retrieved, 6 systematic reviews were selected and assessed for quality according to AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews). Two showed moderate quality. We then updated the most recent review. The updated literature search resulted in 10 additional studies that were included in the qualitative synthesis. The recommendations based on evidence summary and PROMs limitations were presented at the consensus meeting. The group makes the following recommendations: (1) the Hip and Groin Outcome Score (HAGOS) and the International Hip Outcome Tool (iHOT) instruments (long and reduced versions) are the most appropriate PROMs to use in young and middle-aged active adults with hip-related pain; (2) more research is needed into the utility of the HAGOS and the iHOT instruments in a non-surgical treatment context; and (3) generic quality of life measures such as the EuroQoL-5 Dimension Questionnaire and the Short Form Health Survey-36 may add value for researchers and clinicians in this field. We conclude that as none of the instruments shows acceptable quality across various psychometric properties, more methods studies are needed to further evaluate the validity of these PROMS—the HAGOS and iHOT—as well as the other (currently not recommended) PROMS.

show abstract

“…Baseline evaluation was done before index hip arthroscopy. Further outcome evaluations were performed at six weeks, three, six, 12 and 24 months after ACI utilizing three validated scores: EQ-5D, (general health/mental and physical); iHOT33 (pain, hip-specific function, daily living and sports); NAHS (sport activities, function) [ 23 – 25 ].…”

Section: Methodsmentioning

confidence: 99%

Arthroscopic autologous chondrocyte implantation in the hip for the treatment of full-thickness cartilage defects

Thier

Weiß

Fickert

2017

SICOT-J

Self Cite

View full text Add to dashboard Cite

Purpose: Current literature indicates that the appropriate treatment of articular cartilage defects has significant influence on the postoperative outcome after hip arthroscopy. In the hip, arthroscopic treatment of cartilage defects is technically challenging, especially the autologous chondrocyte implantation/matrix-associated autologous chondrocyte implantation (ACI/MACI) procedures. The purpose of this prospective study was to introduce two injectable MACI products with self-adherent properties. Furthermore, we report short-term outcome and review the current literature. Methods: Full-thickness cartilage defects of 29 patients caused by the femoroacetabular impingement (FAI) were treated arthroscopically with an injectable MACI product in a two-step surgical procedure. The patient-related outcome was assessed with International Hip Outcome Tool (iHOT33), Euro-Quol group score (EQ-5D) and Non-Arthritic-Hip-Score (NAHS) at baseline, six weeks, six, 12 and 24 months. Results: Twenty-nine out of 46 patients (27 male/two female) with a mean age of 30.3 years (range 18–45 years) and an average defect size of 2.21 cm2 were available for follow-up after a mean of 19 months (range 6–24 months). All defects were located on the acetabulum International Cartilage Repair Society (ICRS) grade 3A–3D (nine 3A; eleven 3B; six 3C; three 3D). Twenty-six patients had associated labral pathology (23 repair 1–5 anchors; three partial trimming). Twenty-seven defects were caused by the FAI (20 CAM, six combined, one Pincer), two cases were of traumatic cause. An overall statistically significant improvement was observed for all assessment scores at an average follow-up of 19 months. Conclusion: In this study, we present short-term data of new arthroscopic injectable matrix-associated, autologous chondrocyte implants as a treatment option for full-thickness cartilage defects of the hip. All patient-administered assessment scores demonstrated an increase in activity level, quality of life and reduction of pain after a 19-month follow-up. Further randomized controlled trails (RCTs) with comparison of natural history, bone marrow stimulation techniques and MACI of the hip have to approve the results in long-term follow-up.

show abstract

Validation of a German version of the International Hip Outcome Tool 12 (iHOT12) according to the COSMIN checklist

Cited by 31 publications

References 38 publications

Evaluation of the patient acceptable symptom state following hip arthroscopy using the 12 item international hip outcome tool

Evaluation of the patient acceptable symptom state following hip arthroscopy using the 12 item international hip outcome tool

Patient-reported outcome measures for hip-related pain: a review of the available evidence and a consensus statement from the International Hip-related Pain Research Network, Zurich 2018

Arthroscopic autologous chondrocyte implantation in the hip for the treatment of full-thickness cartilage defects

Contact Info

Product

Resources

About